• Latest Posts

German Biotech Unveils Positive Phase II Results for Alzheimer’s

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

ADVERTISEMENT